Rwanda is putting in place modalities to export human plasma to contracted firms, for purposes of producing plasma derived medicinal products (PDMPs). PDMPs are prepared industrially from human plasma by pharmaceutical manufacturers and include products such as immunoglobulins, coagulation factors and albumin, which are life-saving therapies for several chronic and acute life-threatening diseases such as hemophilia and primary immunodeficiency disorders. Several (PDMPs) are included in the WHO Model List of Essential Medicines, which highlights medicines considered to be the most effective and safe to address the major needs in a health system.

Rwanda hopes to get PDMPS for the patients in need of them at a relatively lower price, through the proposed contractual arrangement.

Read more about this in an article published in The New Times.